Amphotericin B in Liposomes: A Novel Therapy for Histoplasmosis

Authors:
  • RTR L Taylor
    R L Taylor
  • DWD M Williams
    D M Williams
  • PCP C Craven
    P C Craven
  • JGJ R Graybill
    J R Graybill
  • DDD J Drutz
    D J Drutz
  • WMW E Magee
    W E Magee

Abstract
Incorporation of amphotericin B into liposomes significantly altered its toxicity, tissue distribution, and efficacy. Compared with intravenously administered amphotericin B-desoxycholate, liposome-amphotericin B showed a reduced acute toxicity and a maximal tolerable dose 9 times greater than amphotericin B-desoxycholate. Liposome-amphotericin B also produced higher tissue and lower serum concentrations than amphotericin B-desoxycholate, and was significantly more effective in prolonging survival of mice infected with Histoplasma capsula- tum. AM REV RESPIR DIS 1982; 125:610-611